Results 181 to 190 of about 66,897 (261)

Cryptococcid Sweet Syndrome in the Setting of Hydralazine‐Induced ANCA Vasculitis: A Case Report

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 4, Page 356-361, April 2026.
ABSTRACT Acute febrile neutrophilic dermatosis, also known as Sweet syndrome, is an inflammatory skin condition characterized by the rapid onset of painful, erythematous plaques or nodules with neutrophilic infiltrate on histology. Rarely, acellular bodies surrounded by vacuolated spaces have been noted within the neutrophilic infiltrate, mimicking ...
Jenna Vroman   +4 more
wiley   +1 more source

Predictors of 30-day hospitalization in patients with worsening heart failure receiving outpatient intravenous diuretics. [PDF]

open access: yesPLoS One
van Maarschalkerwaart WA   +6 more
europepmc   +1 more source

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu‐DOTA‐TATE: A post‐authorisation safety study

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract A post‐authorisation safety study (PASS) was conducted to assess the impact of LysaKare (2.5% Lysine‐Arginine solution) on serum potassium concentrations and its safety/tolerability profile in patients with gastroenteropancreatic neuroendocrine tumours (GEP‐NET) eligible for 177Lu‐DOTATATE treatment.
Johannes Hofland   +12 more
wiley   +1 more source

Early Prediction of Hepatic Decompensation in Cirrhosis Using Optimised XGBoost Models at the Initial Outpatient Hepatology Visit

open access: yesLiver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background and Aims Hepatic decompensation represents a critical transition in cirrhosis, leading to increased morbidity, mortality and healthcare utilisation. Identifying patients at risk of decompensation remains a clinical challenge. We aimed to develop and validate XGBoost models to predict hepatic decompensation at multiple time points ...
Micah Grubert Van Iderstine   +7 more
wiley   +1 more source

Preventing First and Further Decompensation in Advanced Chronic Liver Disease

open access: yesLiver International, Volume 46, Issue 4, April 2026.
ABSTRACT Advanced chronic liver disease (ACLD) remains a major cause of global morbidity and mortality. Preventing hepatic decompensation—both the first event and subsequent recurrences—has become a central therapeutic goal to prolong survival. The transition from the compensated phase (cACLD) to the decompensated phase (dACLD) is driven by clinically ...
Leonardo Corrêa Süffert   +2 more
wiley   +1 more source

Urine Olfactomedin 4 Predicts Furosemide Response and Kidney Replacement Therapy in Critically Ill Children. [PDF]

open access: yesCrit Care Explor
Hasson DC   +14 more
europepmc   +1 more source

Personalised Long‐Term Albumin Treatment Based on Three‐Month Ascites Response in Patients With Decompensated Cirrhosis

open access: yesLiver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background and Aims Long‐term albumin (LTA) is effective for treating ascites in decompensated cirrhosis. This study aims to analyse the clinical courses of patients receiving LTA and provide a 3 month stratification to personalise management integrating LTA with other options.
Enrico Pompili   +18 more
wiley   +1 more source

Neutropenia Associated With Furosemide Administration in a Preterm Infant. [PDF]

open access: yesCase Rep Pediatr
Connolly GK   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy